TMCnet News
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesBOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, “Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,” details how Monte Rosa’s proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes. These findings dramatically expand the actionable target space for MGD drug discovery. “The findings from this landmark publication, featured on the cover of Science, have accelerated our ability to develop first-in-class medicines for historically intractable targets, validating the power of our QuEEN™ discovery engine to create the next generation of molecular glue degrader medicines,” said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa. “We’re already leveraging these insights to advance our growing pipeline of differentiated MGDs and future medicines that have the potential to transform patients' lives.” “Our cutting-edge approach to MGD discovery integrates internal datasets with geometric deep learning to characterize protein surfaces. We have uncovered new rules of engagement between protein targets, small molecules and E3 ligases such as cereblon that we’re actively exploiting via our proprietary QuEEN discovery engine to rationally design exquisitely selective degrader therapies,” said John Castle, Ph.D., Chief Data and Information Officer at Monte Rosa. “This work not only highlights the lexibility of cereblon but also demonstrates our ability to design MGDs that address previously inaccessible, disease-relevant proteins.” Monte Rosa’s QuEEN discovery engine uses custom-built AI/ML algorithms to analyze protein surfaces at unprecedented scale, identifying previously unrecognized surfaces capable of recruiting cereblon for targeted protein degradation. The novel surface features greatly expand the reach of MGDs and redefine the requirements that govern molecular glue-induced target engagement. The paper further details Monte Rosa’s proprietary AI and ML approaches that enabled these discoveries, incorporating geometric deep learning to encode protein surface patches and project geometrical features across the proteome to identify complementary structures that can mediate protein-protein interactions. The analysis successfully identified new protein targets amenable to Monte Rosa’s drug discovery approach, spanning more than 100 target classes, many of which are currently considered to be inaccessible to small molecule binding. The findings significantly broaden Monte Rosa’s potential therapeutic reach in areas including immunology, inflammation and oncology, where the company is currently advancing programs in the clinic. About Monte Rosa Investors Media A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f1f3cc5-631e-4162-a50f-cdbdc3ee864b 
|
